Of note, our treatment approach was not restricted to a distinct sarcoma entity, as different sarcoma cells lines as well as patient-derived sarcoma cells including osteosarcoma, rhabdomyosarcoma, synovial sarcoma liposarcoma and chondrosarcoma were sensitive to treatment with our B7-H3-targeting mAbs. This evidence concerns the gene CD276 and chondrosarcoma.